pSivida develops drugs used to treat eye diseases.

pSivida to raise $US16m

US-focused biotech company pSivida has released pricing details of a $US16 million capital raising, after two weeks of volatile trading in its ASX-listed shares.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

BNiQ Disclaimer